Mirum Presents New Data from LIVMARLI Phase 3 PFIC Study and ALGS Infant Study in Late-Breaker Presentations at The Liver Meeting of AASLD
Mirum Pharmaceuticals reported significant findings from the Phase 3 MARCH study of LIVMARLI (maralixibat), a treatment for progressive familial intrahepatic cholestasis (PFIC). The study met primary and secondary endpoints, showing over 60% response in pruritus and half in serum bile acids versus placebo. Additionally, safety data from the RISE study indicates tolerability in infants with Alagille syndrome (ALGS) starting at two months. Mirum plans to discuss these results with regulatory bodies, highlighting the potential market impact of LIVMARLI.
- Phase 3 MARCH study shows statistically significant efficacy of LIVMARLI in treating PFIC, exceeding expectations.
- Over 60% pruritus response and significant serum bile acid reduction in All-PFIC cohort.
- Safety and tolerability confirmed for infants with ALGS in the RISE study.
- Most common treatment-emergent adverse event was diarrhea; only mild cases reported but indicates potential GI issues.
- Phase 3 MARCH study meets primary endpoint and demonstrates statistical significance across key endpoints in all PFIC types. Receives Best of Liver Meeting distinction.
- RISE study in infants with ALGS shows safety and tolerability of LIVMARLI for ages ≥2 months.
- Real-world evidence highlights LIVMARLI’s safety and tolerability in patients with ALGS.
- Post-AASLD conference call to discuss MARCH data on
“The MARCH-PFIC data provides comprehensive evidence that LIVMARLI is a potentially meaningful treatment option for patients with progressive familial intrahepatic cholestasis (PFIC). The statistically significant reduction in pruritus and serum bile acids, as well as improvements in bilirubin and growth, demonstrate a magnitude of treatment effect which exceeded expectations, suggesting higher doses not only improves response rates, but is also effective across PFIC types,” said
Oral session #5001: Efficacy and safety of maralixibat in patients with progressive familial intrahepatic cholestasis (MARCH-PFIC): a randomized placebo-controlled study
**Nominated for Best of Liver Meeting**
Late-breaker oral presentation by Professor
The Phase 3 MARCH study evaluated LIVMARLI 570 µg/kg BID in 93 patients across a broad range of PFIC types between ages one to 17 years old. The primary analysis (n=31) focused on patients with BSEP deficiency (PFIC2). The secondary analyses evaluated the All-PFIC cohort, which included all PFIC types (n=64). The full-study population of 93 patients was inclusive of the All-PFIC cohort, as well as a supplemental cohort of PFIC patients who had previously undergone surgery, had truncating mutations, no variants found, or other.
The primary and secondary endpoints were met with statistical significance. LIVMARLI demonstrated significant and rapid improvements in pruritus and serum bile acids, consistent across all PFIC types, with treatment effect greater than previously reported, with the higher dose tested in this study. In the All-PFIC cohort, over
Topline results
PFIC2 (n=31) |
||||
Endpoint |
Absolute |
Change |
Effect Size* |
P-value |
|
LIVMARLI |
Placebo |
|
|
Primary: Change from baseline in ItchRO(Obs) severity |
-1.7 |
-0.6 |
-1.0 |
P=0.0098 |
Secondary: Change from baseline in serum bile acid |
-176 |
11 |
-187 |
P=0.0013 |
*Effect size compared the difference between LIVMARLI and placebo, averaged over the last 3 time periods using a repeated measures mixed effect model. Placebo adjusted. Numbers in tables may not sum due to rounding.
All-PFIC (n=64) [PFIC1, PFIC2, PFIC3, PFIC4, PFIC6] |
||||
Endpoint |
Absolute |
Change |
Effect Size* |
P-value |
|
LIVMARLI |
Placebo |
|
|
Secondary: Change from baseline in ItchRO(Obs) severity |
-1.8 |
-0.6 |
-1.2 |
P<0.0001 |
Secondary: Change from baseline in serum bile acid |
-157 |
3 |
-160 |
P<0.0001 |
Secondary: Serum bile acid responders |
51.5 |
6.5 |
45.1 |
P<0.0001 |
*Effect size compared the difference between LIVMARLI and placebo, averaged over the last 3 time periods using a repeated measures mixed effect model. Placebo adjusted.
The most common treatment emergent adverse event was diarrhea, which was predominantly mild and transient, with a median duration of 5.5 days. There were no severe cases. One patient had a treatment emergent adverse event of mild diarrhea that led to discontinuation.
Full-Study (n=93) |
||
Treatment Emergent Adverse Event (TEAE) |
LIVMARLI (n=47) |
Placebo (n=46) |
Any TEAE, n (%) |
47 ( |
43 ( |
Severe TEAE, n (%) |
3 ( |
3 ( |
Serious TEAE, n (%) |
5 ( |
3 ( |
TEAE leading to discontinuation, n (%) |
1 ( |
0 |
TEAE leading to death, n (%) |
0 |
0 |
Most common TEAE Diarrhea, n (%) |
27 ( |
9 ( |
Poster #5021: Safety and tolerability characterization of maralixibat in infants with ALGS from 2 months of age: Interim results from the RISE study
Late-breaker poster presentation By Professor
RISE is evaluating the safety of LIVMARLI in infant patients with ALGS and PFIC, younger than one year of age. The interim analysis only reported data from the ALGS cohort. Patients (n=8) received 380 µg/kg of LIVMARLI once per day. The youngest ALGS patient in the study was two months of age, with an average age of seven months. Safety during the study was assessed by treatment-emergent adverse events (TEAEs) and change from baseline to week 13. TEAEs were mostly grade 1 in severity and unrelated to LIVMARLI. Four patients experienced seven serious adverse events which were unrelated to LIVMARLI, all resolved, and none required a change in dose or discontinuation of LIVMARLI.
Based on the safety and tolerability data observed in RISE, LIVMARLI may be an effective treatment option for ALGS patients as young as two months of age.
Poster #4807: Real-world safety experience in patients with Alagille syndrome treated with maralixibat
Poster presented by Dr.
The objective of the study was to report real-world safety observations for patients enrolled in the LIVMARLI global expanded access program. All patients received LIVMARLI with a target dose of 380 µg/kg. The data cut included 37 patients. TEAEs were defined as those occurring on or after the first dose of LIVMARLI and within seven days from the last medication dose.
The majority of TEAEs were mild in severity and unrelated to LIVMARLI. Only one treatment discontinuation occurred which was potentially related to LIVMARLI due to transaminase elevation (grade 3) of unknown clinical significance. Overall, treatment-related gastrointestinal adverse events were observed in
To view all presentations, visit the Publications and Presentations section of Mirum’s website.
Data Discussion and Q3 Business Update
Mirum will be hosting a conference call on
About LIVMARLI® (maralixibat) oral solution
LIVMARLI® (maralixibat) oral solution is an orally administered, once-daily, ileal bile acid transporter (IBAT) inhibitor approved by the
LIVMARLI is currently being evaluated in late-stage clinical studies in other rare cholestatic liver diseases including an open-label extension study in progressive familial intrahepatic cholestasis (PFIC), and in biliary atresia. LIVMARLI has received Breakthrough Therapy designation for ALGS and PFIC type 2 and orphan designation for ALGS, PFIC and biliary atresia. To learn more about ongoing clinical trials with LIVMARLI, please visit Mirum’s clinical trials section on the company’s website.
IMPORTANT SAFETY INFORMATION
LIVMARLI can cause side effects, including:
Changes in liver tests. Changes in certain liver tests are common in patients with Alagille syndrome and can worsen during treatment with LIVMARLI. These changes may be a sign of liver injury and can be serious. Your healthcare provider should do blood tests before starting and during treatment to check your liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including nausea or vomiting, skin or the white part of the eye turns yellow, dark or brown urine, pain on the right side of the stomach (abdomen) or loss of appetite.
Stomach and intestinal (gastrointestinal) problems. LIVMARLI can cause stomach and intestinal problems, including diarrhea, stomach pain, and vomiting during treatment. Tell your healthcare provider right away if you have any of these symptoms more often or more severely than normal for you.
A condition called Fat Soluble Vitamin (FSV) Deficiency caused by low levels of certain vitamins (vitamin A, D, E, and K) stored in body fat. FSV deficiency is common in patients with Alagille syndrome but may worsen during treatment. Your healthcare provider should do blood tests before starting and during treatment.
Other common side effects reported during treatment were bone fractures and gastrointestinal bleeding.
About
Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. LIVMARLI, an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 clinical trial for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b clinical trial for patients with biliary atresia. In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC.
Mirum’s second investigational treatment, volixibat, an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the VISTAS Phase 2b clinical trial for adults with primary sclerosing cholangitis, the OHANA Phase 2b clinical trial for pregnant women with intrahepatic cholestasis of pregnancy, and the VANTAGE Phase 2b clinical trial for adults with primary biliary cholangitis.
Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.
Forward-Looking Statements
This press release includes forward-looking statements pertaining to the Company’s planned participation at a scientific conference, including data presentation title and synopsis, which may include discussion of the Company’s clinical and research data, including the discovery, development, and commercialization of our product candidates and technologies, the therapeutic potential of Company products, the continuation of our clinical trials, and any potential future collaborations. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those relating to our preclinical research and clinical programs and other risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those relating to our preclinical research and clinical programs and other risks identified under the heading “Risk Factors” included in our most recent Form 10-Q and Form 10-K filings and in other future filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20221107005899/en/
Media Contact:
media@mirumpharma.com
Investor Contacts:
ir@mirumpharma.com
ir@mirumpharma.com
Source:
FAQ
What were the results of the Phase 3 MARCH study for MIRM?
When is the conference call to discuss the MARCH data for MIRM?
What is LIVMARLI's safety profile based on the RISE study?
What is the market potential for MIRM following the MARCH study results?
